Systemic treatment of AIDS-related Kaposi sarcoma: Current status and perspectives

Cancer Treatment Reviews

Volumn 32, Issue 6, 2006, Pages 445-455

  Vanni, Tazio ^a   Sprinz, Eduardo ^b   Machado, Marcelo Warlet ^b   Santana, Rodrigo de C ^a   Fonseca, Benedito Antonio L ^a   Schwartsmann, Gilberto ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

AIDS; Kaposi's Sarcoma; Treatment

Indexed keywords

ALITRETINOIN; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTHRACYCLINE; BLEOMYCIN; CYTOTOXIC AGENT; DAUNORUBICIN; DEXAMETHASONE; DIDANOSINE; DIPHENHYDRAMINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; IMATINIB; INDINAVIR; LIPOSOME; MATRIX METALLOPROTEINASE INHIBITOR; PACLITAXEL; PEGINTERFERON; PENTOSAN POLYSULFATE; PROTEINASE INHIBITOR; RANITIDINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; THALIDOMIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; AIDS PATIENT; AIRWAY OBSTRUCTION; ALOPECIA; ARTHRALGIA; BACKACHE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DYSPNEA; EPIDEMIC; FLUSHING; HAND FOOT SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; KAPOSI SARCOMA; LEUKOPENIA; LOW DRUG DOSE; MYALGIA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PATIENT CARE; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTEMIC THERAPY; UGANDA; VIRUS LOAD; WESTERN HEMISPHERE; ZIMBABWE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CLINICAL TRIALS; HUMANS; INTERFERONS; LIPOSOMES; MALE; PACLITAXEL; SARCOMA, KAPOSI;

EID: 33748193685     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.06.001     Document Type: Review

References (78)

1. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 92 (2000) 1823-1830
2. Grulich A.E., Li Y., McDonald A.M., et al. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS 15 (2001) 629-633
3. Mbulaiteye S.M., Parkin D.M., and Rabkin C.S. Epidemiology of AIDS-related malignancies: an international perspective. Hematol Oncol Clin N Am 17 (2003) 673-696
4. Mocroft A., Kirk O., Clumeck N., Gargalianos-Kakolyris P., Trocha H., Chentsova N., et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. Cancer 100 12 (2004) 2644-2654
5. Sitas F., and Newton R. Kaposi's sarcoma in South Africa. J Natl Cancer Inst 28 (2000) 1-4
6. Wabinga H.R., Parkin D.M., Wabwire-Mangen F., and Nambooze S. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997. Br J Cancer 82 (2000) 1585-1592
7. Echimane A.K., Ahnoux A.A., Adoubi I., et al. Cancer incidence in Abidjan, Ivory Coast: first results from the cancer registry, 1995-1997. Cancer 89 (2000) 653-663
8. Bassett M.T., Chokunonga E., Mauchaza B., Levy L., Ferlay J., and Parkin D.M. Cancer in the African population of Harare, Zimbabwe, 1990-1992. Int J Cancer 63 (1995) 9-36
9. Parkin D.M., Wabinga H., Nambooze S., and Wabwire-Mangen F. AIDS-related cancers in Africa: maturation of the epidemic in Uganda. AIDS 13 (1999) 2563-2570
10. Levine A.M., and Tulpule A. Clinical aspects and management of AIDS-related Kaposi's sarcoma. Eur J Cancer 37 (2001) 1288-1295
11. Von Roenn J.H. Clinical Presentations and standard therapy of AIDS-associated Kaposi's sarcoma. Hematol Oncol Clin N Am 17 (2003) 747-762
12. Hengge U.R., Ruzicka T., Tyring S.K., Stuschke M., Roggendorf M., Schwartz R.A., et al. Update on Kaposi's sarcoma and other HHV8 associated disease. Part 1: epidemiology, environmental predisposition, clinical manifestation, and therapy. Lancet Infect Dis 2 (2002) 281-292
13. Dezube B.J., Pantanowitz L., and Aboulafia D.M. Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment. AIDS Read 14 5 (2004) 236-253
14. Krown S.E., Metroka C., and Wernz J.C. Kaposi's sarcoma and the acquired immune deficiency syndrome: a proposal for an uniform evaluation, response and staging criteria. J Clin Oncol 7 (1989) 1201-1207
15. Krown S.E., Testa M.A., Huang J., et al. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trial Group staging classification. J Clin Oncol 15 (1997) 3085-3092
16. Harris A.H., Osborne R.H., Streeton C.L., and McNeil H. Quality of life and Kaposi sarcoma: using preference techniques to value the health gains from treatment. Support Care Cancer 10 (2002) 486-493
17. Osoba D., Northfelt D.W., Budd D.W., and Himmelberger D. Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: a randomized trial of pegylated-lipossomal doxorubicin versus doxorubicin, bleomycin, and vincristine. Cancer Invest 19 (2001) 573-580
18. Nasti G., Talamini R., Antinori A., et al. AIDS-related Kaposi Sarcoma: evaluation of potential new prognostic factors and assessment of AIDS Clinical Trial Group Staging System in the HAAART Era- the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive from Antiretroviral. J Clin Oncol 21 (2003) 2876-2882
19. Northfelt D.W., Dezube B.J., Thommes J.A., Miller B.J., Fischl M.A., Friedman-Kien A., et al. Pegylated-lipossomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16 (1998) 2445-2451
20. Northfelt D.W., Dezube B.J., Thommes J.A., Levine R., Von Roenn J.H., Dosik G.M., et al. Efficacy of pegylated-lipossomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 15 2 (1997) 653-659
21. Gill P.S., Wernz J., Scadden D.T., et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS related Kaposi's sarcoma. J Clin Oncol 14 (1996) 2353-2364
22. FDA homepage: http://www.accessdata.fda.gov/scripts/cder/onctools/organ.cfm. Accessed for the last time in January 31, 2005.
23. Nasti G., Martellota F., Berretta M., Mena M., Fasan M., Di Ferri G., et al. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immuno deficiency syndrome-related Kaposi sarcoma. Cancer 98 (2003) 2440-2446
24. Martinelli C., Zazzi M., Ambu S., et al. Complete regression of AIDS-related Kaposi's sarcoma-associated human herpersvirus-8 during therapy with indinavir. AIDS 12 (1998) 1717-1719
25. Cattelan A.M., Calabro M.L., Aversa S.M.L., Zanchetta M., Meneghetti F., De Rossi A., et al. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur J Cancer 51 (1999) 1809-1815
26. Niehues T., Horneff G., Megahed M., et al. Complete regression of AIDS-related Kaposi's sarcoma in AIDS. AIDS 13 (1999) 1148-1149
27. Tirelli U., and Bernardi D. Impact of HAART on the clinical management of AIDS-related cancers. Eur J Cancer 37 (2001) 1320-1324
28. Murdaca G., Campelli A., Sett M., et al. Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor. AIDS 16 (2002) 304-305
29. Paparizos V., Kyriakis K.P., Papastamopoulos V., et al. Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone. J Acq Immu Def Synd 30 (2002) 257-258
30. Bower M., Fox P., Fife K., Gill J., Nelson M., and Gazzard B. Highly active antiretroviral therapy prolongs time to treatment failure in Kaposi's sarcoma. AIDS 13 (1999) 2105-2111
31. Leitch H., Trudeau M., and Routy J.P. Effect of protease inhibitors-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy. HIV Clin Trials 4 (2003) 107-114
32. Holkova B., Takeshita K., Cheng D.M., Volm M., Wasserheit C., Demopoulos R., et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol 19 (2001) 3848-3851
33. Krown S.E. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol 22 (2004) 399-402
34. Lebbe C., Blum L., Pellet C., et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV related Kaposi's sarcoma. AIDS 12 (1998) F45-F49
35. Boivin G., Gaudreau A., and Routy J.P. Evaluation of the human herpesvirus 8 DNA load in blood and Kaposi's sarcoma skin lesions from AIDS patients on highly active antiretroviral therapy. AIDS 14 (2000) 1907-1910
36. Pellet C., Chevret S., Blum L., et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J Invest Dermatol 117 (2001) 858-863
37. Gill J., Bourboulia D., Wilkinson J., et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infections in patients with or without Kaposi sarcoma. J Acq Immun Def Synd 31 (2002) 384-390
38. Sgadari C., Monini P., Barillari, and Ensoli B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumor growth. Lancet Oncol 4 (2003) 537-547
39. Pati S., Pelser C.B., Dufraine J., Bryant J.L., Reitz Jr. M.S., and Weichold F.F. Antitumorigenic effect of HIV protease inhibitors ritonavir: inhibition of Kaposi sarcoma. Blood 99 (2002) 3771-3779
40. US Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. October 29, 2004. Available from: http://aidsinfo.nih.gov/guidelines/.
41. BHIV Writing Committee on behalf of the BHIV Executive Committee. Guidelines for the treatment of HIV infected adults with antiretroviral therapy. HIV Med, British HIV Association 2001;2:276-313. Available from: http://www.aidsmap.com.
42. Postsmouth S., Stebbing J., Gill J., Mandalia S., Bower M., Nelson M., et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 17 11 (2003) F17-F22
43. Stebbing J., Postsmouth S., Nelson M., Mandalia S., Kandil H., Alexander N., et al. The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcoma. Int J Cancer 108 4 (2004) 631-633
44. Schwartsmann G., Stefani S., and Villaroel R.U. The systemic treatment of AIDS-related Kaposi's sarcoma. Cancer Treat Rev 24 (1998) 415-424
45. Minotti G., Menna P., Salvatorelli E., Cairo G., and Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Ver 56 (2004) 185-229
46. Stewart J.S.W., Jabonowski H., Goebel F.D., et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 16 (1998) 683-691
47. Dedicoat M, Vaithilingum M, Newton R. Treatment of Kaposis sarcoma in HIV-1 infected individuals with emphasis on resource poor settings (Cochrane Review). In: The Cochrane library, Issue 2, 2004. Oxford: Update Software.
48. Mitsuyasu R., Von Roenn J., Krown S., et al. Comparison study of liposomal doxorubicin (DOX) alone or with bleomycin and vincristine (DBV) for treatment of advanced AIDS-associated Kaposi's sarcoma (AIDS-KS): AIDS Clinical Trials Group (ACTG) protocol 286 [abstract]. Proc Am Soc Clin Oncol 16 (1997) 55a
49. Martín-Carbonero L., Barrios A., Saballs P., Sirera G., Santos J., Palacios R., et al. Pegylated lipossomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS 18 (2004) 1737-1740
50. Rosenthal E., Poizot-Martin I., Saint-Marc T., Spano J.P., and Cacoub P. Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma. Am J Clin Oncol 25 (2002) 57-59
51. Tulpule A., Yung R.C., Wernz J., et al. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma. J Clin Oncol 16 (1998) 3369-3374
52. Laubenstein L.S., Krigel R.L., Odajnyk C.M., et al. Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin and vinblastine. J Clin Oncol 2 (1984) 1115-1120
53. Girard P.M., Bouchaud O., Guetschel A., et al. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated Kaposi's sarcoma. AIDS 10 (1996) 753-757
54. Sgadari C., Toschi E., Palladino C., et al. Mechanism of paclitaxel activity in Kaposi's sarcoma. J Immunol 165 (2000) 509-517
55. Welles L., Saville M., Lietzau J., et al. Phase III trial with dose titration of paclitaxel for the therapy of human immuno deficiency virus-associated kaposi's sarcoma. J Clin Oncol 16 (1998) 1112-1121
56. Saville M.W., Leitzau J., Pluda J.M., et al. Treatment of HIV associated Kaposi's sarcoma with paclitaxel. Lancet 346 (1995) 26-28
57. Gill P.S., Tulpule A., Espina B.M., et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol 17 (1999) 1876-1883
58. Tulpule A., Groopman J., Saville M.W., et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 95 (2002) 147-154
59. Antoniou T., and Tseng A.L. Interactions between antiretroviral drugs and antineoplastic drug therapy. Clin Pharmacokinet 44 2 (2005) 111-145
60. WHO essentials drugs list 13th edition, revised in April 2003. Available from WHO homepage: http://www.who.int/medicines/.
61. Gill P., Rarick M., McCutchan J.A., et al. Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. Am J Med 90 (1991) 427-433
62. Laubestein L.J., Kriegler R., Odajynk C., et al. Treatment of epidemic Kaposi's sarcoma with VP-16 (etoposide) or a combination of doxorubicin, bleomycin and vinblastine. J Clin Oncol 2 (1984) 1115-1120
63. Evans S.R., Krown S.E., Testa M.A., Cooley T.P., and Van Roenn J.H. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol 20 15 (2002) 3236-3241
64. Sprinz E., Caldas A.P., Mans D.R., et al. Fractionated doses of oral etoposide in the treatment of patients with AIDS-related Kaposi sarcoma. Am J Clin Oncol 24 (2001) 177-184
65. Schwartsmann G., Sprinz E., Stefani S.D., et al. Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma (AIDS-KS) with no prior exposure to cytotoxic therapy. J Clin Oncol 15 (1997) 2118-2124
66. Krown S.E. Management of Kaposi sarcoma: the role of interferon and thalidomide. Curr Opin Oncol 13 (2001) 374-381
67. Antman K., and Chang Y. Kaposi's sarcoma. N Engl J Med 342 (2000) 1027-1038
68. Krown S.E., Ping L., Von Roenn J.H., et al. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS Clinical Trials Group Study. J Interf Cytok Res 22 (2002) 295-303
69. Levine A.M. The treatment of AIDS-related cancers. Lancet Oncol 4 (2003) 576-577
70. Sikora K., Advani S., Koroltchouk V., Magrath I., Levy L., Pinedo H., Schwartsmann G., Tattersall M., and Yan S. Ann Oncol 10 (1999) 385-390
71. Krigel R.L., Slywotzky C.M., Longberg M., et al. Treatment of epidemic Kaposi's sarcoma with a combination of interferon alpha and etoposide. J Biol Resp Modif 7 (1988) 359-364
72. Shepherd F.A., Evans W., Garvey B., et al. Combination chemotherapy and a-interferon in the treatment of Kaposi's sarcoma associated to acquired immune deficiency syndrome. Can Med Assoc J 139 (1988) 635-639
73. Schwartsmann G., Sprinz E., Kalakun L., Yamagushi N., Sander E., Grivicich I., et al. Phase II study of Pentosan Polysulfate (PPS) in patients with AIDS-related Kaposi's sarcoma. Tumori 82 (1996) 360-363
74. Cianfrocca M., Cooley T.P., Lee J.Y., Rudek M.A., Scadden D.T., Lee R., et al. Matrix metalloproteinase inhibitors COL-3 in the treatment of AIDS-related Kaposi's sarcoma: A phase I AIDS Malignancy Consortium Study. J Clin Oncol 20 (2002) 153-159
75. Koon H.B., Bubley G.J., Pantanowitz L., Masiello D., Smith B., Crosby K., et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 23 5 (2005) 982-989
76. Glesby M.J., Hoover D.R., Weng S., et al. Use of anti herpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis 173 (1996) 1477-1480
77. Hammoud Z., Parenti D.M., Simon G.L., et al. Abatement of cutaneous Kaposi's sarcoma associated with cidofovir treatment. Clin Infect Dis 26 (1998) 1233
78. Miles S.A., Dezube B.J., Lee J.Y., Krown S.E., Fletcher M.A., Saville M.W., et al. AIDS Malignancy Consortium. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS 16 3 (2002) 421-429